医学新闻与研究

In a JAMA report using rapid ultraoxygenated recovery with extended preservation, 30-day survival reached 96% with 4% severe primary graft dysfunction, potentially easing adoption where normothermic regional perfusion is restricted.

Phase 1 dose-escalation data for ZW191 reported cORR 78.6% in FRα-high and 47.4% in FRα-low/negative PROC, with median DoR not reached and grade 3 or higher TEAEs in 55%.

Approval of tebipenem pivoxil is supported by a global randomized double-blind noninferiority trial in 1,690 hospitalized adults showing comparable composite clinical and microbiologic response to IV imipenem-cilastatin for 7 to 10 days.

Cluster crossover RCT in 23 US hospitals found Eat, Sleep, Console infants reached medical readiness 2.3 days sooner vs scheduled taper with no safety signal through 3 months, though 35% still required scheduled dosing.